Abstract
Selective protection of the normal host tissues from the toxic effects of anticancer agents would allow the use of higher, probably more effective, doses of the drugs. It has been demonstrated that delayed high-dose uridine administration after 5-fluorouracil decreases the extent of myelosuppression and causes faster regeneration of the bone marrow. We studied the biochemical consequences of the gastrointestinal toxicity caused by 5-fluorouracil and the potential of high-dose uridine treatment to influence these adverse effects. 5-Fluorouracil caused dose-related decreases in the biochemical parameters (thymidine kinase, sucrase, maltase, alkaline phosphatase) selected as early markers of the impaired metabolic activity of the intestinal mucosa. The nadir of the biochemical changes was reached between 24 h and 72 h after 5-fluorouracil treatment, and complete regeneration of the mucosa took 6–7 days. Delayed high-dose uridine administration failed to mitigate the severity of the gastrointestinal damage that ensued after 5-fluorouracil treatment, but caused significantly earlier regeneration of the mucosa.
Similar content being viewed by others
References
Bateman JR (1971) 5-Fluorouracil given once weekly. Comparison of intravenous and oral administration. Cancer 28:907
Bessey OA, Lowry OH, Brock MI (1965) Determination of alkaline phosphatase activity in serum withp-nitrophenylphosphate. In: Bergmeyer HU (ed) Methods of enzymatic analysis. Verlag Chemie, Weinheim/Academic Press, New York London, p 783
Dahlquist A (1968) Assay of intestinal disaccharidases. Anal Biochem 22:99
Grem JL (1990) Fluorinated pyrimidines. In: Chabner B. H., Collins F. M. (eds) Cancer chemotherapy. Principles and practice. Lippincott, Philadelphia, p 180
Groeningen CJ van, Leyva A, Kraal I, Peters GJ, Pinedo HM (1986) Clinical and pharmacokinetic studies of prolonged administration of high dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 70:745
Groeningen CJ van, Peters GJ, Leyva A, Laurensse E, Pinedo HM (1989) Reversal of 5-fluorouracil induced myelosuppression by prolonged administration of high dose uridine. J Natl Cancer Inst 81:157
Groeningen CJ van, Peters GJ, Nadal JC, Laurensse E, Pinedo HM (1991) Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 83:437
Harrison SD, Denine EP, Peckham JC (1978) Qualitative and quantitative toxicity of single and sequential sublethal doses of 5-fluorouracil in BDF1 mice. Cancer Treat Rep 62:533
Hartree EF (1970) Determination of protein. A modification of the Lowry method which gives a linear photometric response. Anal Biochem 48:422
Hartwich G (1974) Side effects of a cytostatic treatment on the gastrointestinal tract. Acta Hepatogastroenterol 21:89
Houghton JA, Houghton PJ, Wooten PS (1979) Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine. Cancer Res 39:2406
Klemperer C, Haynes J (1968) Thymidine kinase in rat liver during development. Biochem J 108:541
Klubes P, Cerna I (1983) Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res 43:3182
Klubes P, Cerna I, Meldon MA (1982) Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol 8:17
Kralovanszky J, Prajda N, Kerpel-Fronius S, Szentirmay Z (1981) Biological model system for investigating gastrointestinal side effects caused by cytostatic agents. In: Mòzsik G, Hänninen O., Jàvor T. (eds) Gastrointestinal defence mechanisms. Pergamon Press London/ Akademiai Kiado, Budapest, p 327
Kralovanszky J, Prajda N, Kerpel-Fronius S, Gal F, Kiss F (1988) Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP) carboplatin (CBDCA) and iproplatin (CHIP). Cancer Chemother Pharmacol 21:40
Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW (1982) High dose 5-fluorouracil with delayed uridine “rescue” in mice. Cancer Res 42:3964
Mózsik Gy, Snodgrass W (1986) Clinical gastrointestinal toxicology: In: Rozman K (ed) Gastrointestinal toxicology, Elsevier, Amsterdam New York Oxford, p 436
Peters GJ, Groeningen CJ van, Laurensee EJ, Lankelma J, Leyva A, Pinedo HM (1987) Uridine induced hypothermia in mice and rats in relation plasma and tissue levels of uridine and its metabolite. Cancer Chemother Pharmacol 20:101
Peters GJ, Van Dijk J, Laurensse E, Groeningen CJ van, Lankelma J, Leyva A, Nadal JC, Pinedo HM (1988) In vitro biochemical and in vivo biological studies of the uridine rescue of 5-fluorouracil. Br J Cancer 57:259
Peters GJ, Groeningen CJ van (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 2:469
Pinedo HM, Peters GJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653
Prajda N, Kralovanszky J, Kerpel-Fronius S, Gal F, Szentirmay Z (1985) Enzymological and morphological changes in rat intestinal mucosa following treatment with alkylating sugar alcohol derivatives. Anticancer Res 5:451
Roche AC, Bognel JCI, Bognel C, Bernier JJ (1970) Correlation between the histological changes and glucose intestinal absorption following a single dose of 5-fluorouracil. Digestion 3:195
Sawyer RC, Stolfi RL, Spiegelman S, Martin DS (1984) Effect of uridine on the metabolism of 5-fluorouracil in the CD8F1 murine mammary carcinoma system. Pharmacol Res 2:69
Van de Wilt CL, Marinelli A, Smid K, Cloos J, Pinedo HM, Peters GJ (1992) Inhibition of thymidylate synthase (TS). In normal tissues a toxic side effect of 5-fluorouracil (5FU). Proceedings of The 83rd Annual Meeting of the American Association for Cancer Research, abstract 2536
Weckbecker G (1991) Biochemical pharmacology and analysis of Fluoropyrimidines alone and in combination with modulators. Pharmacol Ther 50:367
Weiser MM (1973) Intestinal epithelial cell surface membrane glycoprotein synthesis. J Biol Chem 248:2536
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kralovanszky, J., Prajda, N., Kerpel-Fronius, S. et al. Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine. Cancer Chemother. Pharmacol. 32, 243–248 (1993). https://doi.org/10.1007/BF00685843
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685843